» Articles » PMID: 17218562

Endothelin-1/endothelin-3 Ratio: a Potential Prognostic Factor of Pulmonary Arterial Hypertension

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2007 Jan 16
PMID 17218562
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pulmonary arterial hypertension (PAH) is a rare condition characterized by elevated pulmonary artery pressure leading to right-heart failure and death. Endothelin (ET)-1 has been shown to play a significant pathogenic role in PAH. ET-3 has not yet been investigated in PAH.

Methods: ET-1 and ET-3 plasma concentrations were measured in 33 PAH patients prior to any specific PAH therapy and in 9 control subjects. In PAH patients, hemodynamic parameters measured by right-heart catheterization, 6-min walk distance (6MWD), New York Heart Association (NYHA) functional class, and time until lung transplantation or death were recorded.

Results: In patients with PAH, levels of ET-1 were increased while those of ET-3 were decreased, as compared to control subjects (p < 0.005 for both comparisons). ET-1/ET-3 ratio varied little in control subjects, while it increased threefold in PAH patients (p < 0.0001). ET-1 correlated positively with right atrial pressure (RAP), indexed total pulmonary resistance, and negatively with cardiac index and venous saturation of oxygen (Svo(2)). ET-3 correlated positively with 6MWD. ET-1/ET-3 ratio correlated positively with RAP, negatively with Svo(2) and 6MWD, and was also associated with NYHA functional class. ET-1/ET-3 ratio was associated with prognosis in this sample of PAH patients treated with specific therapies.

Conclusions: PAH is characterized by elevated ET-1 and ET-1/ET-3 ratio and decreased ET-3 plasma concentrations. All of them correlate with hemodynamic and clinical markers of disease severity. ET-1/ET-3 ratio might be a novel prognostic factor in PAH. These preliminary data should be validated in a large prospective multicenter cohort of PAH patients.

Citing Articles

Machine Learning Analysis of Predictors for Inhaled Nitric Oxide Therapy Administration Time Post Congenital Heart Disease Surgery: A Single-Center Observational Study.

Niiyama S, Nakashima T, Ueno K, Hirahara D, Nakajo M, Madokoro Y Cureus. 2024; 16(7):e65783.

PMID: 39082048 PMC: 11288644. DOI: 10.7759/cureus.65783.


Endotyping COPD: hypoxia-inducible factor-2 as a molecular "switch" between the vascular and airway phenotypes?.

Myronenko O, Foris V, Crnkovic S, Olschewski A, Rocha S, Nicolls M Eur Respir Rev. 2023; 32(167).

PMID: 36631133 PMC: 9879331. DOI: 10.1183/16000617.0173-2022.


Common Variation in Regulatory Regions Highlights the Role of PPARγ as a Key Regulator of Endothelin .

Lago-Docampo M, Solarat C, Mendez-Martinez L, Baloira A, Valverde D Front Cardiovasc Med. 2022; 9:823133.

PMID: 35282351 PMC: 8913939. DOI: 10.3389/fcvm.2022.823133.


Pulmonary hypertension: Proteins in the blood.

Wilkins M Glob Cardiol Sci Pract. 2020; 2020(1):e202007.

PMID: 33178814 PMC: 7592080. DOI: 10.21542/gcsp.2020.7.


Metformin prevents the development of monocrotaline-induced pulmonary hypertension by decreasing serum levels of big endothelin-1.

Yoshida T, Matsuura K, Goya S, Ma D, Shimada K, Kitpipatkun P Exp Ther Med. 2020; 20(6):149.

PMID: 33093887 PMC: 7571338. DOI: 10.3892/etm.2020.9278.